PolyPid (PYPD) Return on Capital Employed (2020 - 2026)
PolyPid (PYPD) posted Return on Capital Employed of 242.21% for Q1 2026, up 23.69% sequentially from 195.82% in Q4 2025, and down 9666.0% YoY from 2.53% in Q1 2025.
PolyPid (PYPD) Return on Capital Employed (2020 - 2026) Analysis & Trends
PolyPid has reported Return on Capital Employed for 7 years, with the latest figure at 242.21% in Q1 2026.
- Quarterly Return on Capital Employed fell 9666.0% year-over-year to 242.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 242.21% (down 9666.0% YoY) and the FY2025 annual result came in at 205.73%, up 16235.0% from the prior year.
- Return on Capital Employed rose to 242.21% in Q1 2026 per PYPD's latest filing, from 195.82% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 338.87% in Q1 2025 and troughed at 114.67% in Q2 2023.
- A 5-year average of 201.76% and a median of 195.82% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 15145 bps in 2024, then plunged 15157 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 203.36% in 2022, then rose by 3 bps to 210.45% in 2023, then surged by 37 bps to 288.19% in 2024, then slumped by 32 bps to 195.82% in 2025, then grew by 24 bps to 242.21% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 242.21%, 195.82%, and 132.54% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 298.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.55% |
| Mar 31, 2026 | 242.21% |
| Dec 31, 2025 | 195.82% |
| Sep 30, 2025 | 132.54% |
| Jun 30, 2025 | 230.91% |
| Mar 31, 2025 | 338.87% |
| Dec 31, 2024 | 288.19% |
| Sep 30, 2024 | 284.11% |
| Jun 30, 2024 | 194.51% |
| Mar 31, 2024 | 208.96% |
| Dec 31, 2023 | 210.45% |
| Sep 30, 2023 | 132.66% |
| Jun 30, 2023 | 114.67% |
| Mar 31, 2023 | 153.37% |
| Dec 31, 2022 | 203.36% |
| Sep 30, 2022 | 182.16% |
| Jun 30, 2022 | 178.61% |
| Mar 31, 2022 | 138.55% |
| Dec 31, 2021 | 105.82% |
| Sep 30, 2021 | 71.49% |